Celator Pharmaceuticals, Inc announced that it agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

Celator is advancing a number of its own programs based on the Company's proprietary nano-scale delivery platforms. The Company has announced positive results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy in patients with newly diagnosed acute myeloid leukemia.  The study showed that patients treated with CPX-351 demonstrated a higher aplasia rate, a higher remission rate (including complete remissions [CR] and complete remissions with incomplete neutrophil/platelet recovery [CRi]), lower induction mortality, improved median event-free survival (EFS), and improved median overall survival (OS).  Additionally, patients with secondary AML treated with CPX-351 experienced a statistically significant improvement in survival (p=0.01) with median overall survival of 12.1 months versus 6.1 months.

CPX-351 is one of a pipeline of investigational cancer therapies developed using Celator's CombiPlex(R) drug-ratio technology.

Source:

Celator Pharmaceuticals, Inc